TL;DR
Neuropeptide FF (NPFF) is an endogenous octapeptide (FLFQPQRF-NH2) first isolated from bovine brain in 1985. It belongs to the RFamide peptide family and signals through two G protein-coupled receptors, NPFFR1 (GPR147) and NPFFR2 (GPR74). NPFF is best known as an "anti-opioid" peptide that modulates morphine tolerance, dependence, and opioid-induced hyperalgesia, but research has also implicated it in blood pressure regulation, thermoregulation, feeding behavior, and neuroendocrine signaling. It is not an FDA-approved drug. All information below is for research and educational purposes only.
> Research Use Only (RUO) Disclaimer: Neuropeptide FF is not approved by the FDA for human use, diagnosis, treatment, cure, or prevention of any disease. It is not a dietary supplement. Content on this page is intended strictly for laboratory and academic research reference. Any handling of NPFF or related research peptides should be confined to qualified research settings following institutional biosafety protocols.
What Is Neuropeptide FF?
Neuropeptide FF (NPFF) was isolated from bovine brain in 1985 by Yang and colleagues, who used antibodies raised against the molluscan neuropeptide FMRFamide to screen mammalian tissue for cross-reactive material (Yang et al., 1985, PNAS). That search turned up an eight-amino-acid peptide with the sequence Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 (FLFQPQRF-NH2), sharing the characteristic C-terminal Arg-Phe-NH2 ("RFamide") motif with the invertebrate FMRFamide family.
NPFF is encoded by the NPFF gene, which also produces a related peptide, neuropeptide AF (NPAF), through alternative processing of the same precursor. The gene and its peptide products are highly conserved across human, bovine, rat, and mouse tissue, and NPFF-immunoreactive neurons and fiber networks are concentrated in brain regions tied to pain processing, autonomic control, and neuroendocrine regulation — most densely in the hypothalamus, but also in the dorsal horn of the spinal cord, the nucleus tractus solitarius, and the periaqueductal gray (PMC3566396).
NPFF sits within the broader RFamide peptide family, a group of structurally related signaling peptides that share the RF-NH2 C-terminus and include kisspeptin, QRFP/26RFa, prolactin-releasing peptide (PrRP), and RFRP-1/RFRP-3 (the mammalian orthologs of gonadotropin-inhibitory hormone, GnIH). Several of these family members are covered in separate research profiles on this site — see the 26RFa/QRFP article and PrRP article for comparison across the family.
NPFF Receptors: NPFFR1 and NPFFR2
NPFF acts through two class-A GPCRs that couple predominantly to inhibitory Gi/o proteins:
- •NPFFR1 (also called GPR147 or OT7T022)
- •NPFFR2 (also called GPR74 or HLWAR77)
The two receptors share roughly 68% sequence similarity but display distinct ligand preferences and, in several experimental paradigms, opposing physiological effects. NPFFR1 preferentially binds RFRP-1 (NPVF) and RFRP-3 (GnIH), while NPFFR2 is more selectively and potently activated by NPFF and NPAF (PMC12069643).
2025 brought a wave of structural biology on this receptor pair. Cryo-EM studies published in Cell Reports resolved four NPFFR1/NPFFR2 structures bound to NPFF or NPVF, showing that the C-terminal RF-amide motif docks in a conserved orthosteric pocket across both receptors, while variation in extracellular loop 2 (ECL2) and the receptor N-terminus drives subtype selectivity (Structural basis of peptide recognition, Cell Reports, 2025; PubMed 40839429). A companion paper in Protein & Cell used similar structural and mutagenesis approaches to characterize NPFFR1 specifically, reinforcing the hypothesis that NPFFR1 and NPFFR2 may exert opposing roles in pain modulation — NPFFR1 behaving as the dominant anti-opioid/pro-nociceptive receptor, and NPFFR2 behaving as antinociceptive and opioid-potentiating (PMC13107563; DOI 10.1093/procel/pwaf090).
This structural clarity is significant because it gives medicinal chemists, for the first time, a rational template for designing receptor-subtype-selective NPFF ligands — a long-standing bottleneck in the field, since most classic NPFF ligands (including the peptide NPFF itself) engage both receptors non-selectively.
The Anti-Opioid System: NPFF and Opioid Tolerance
NPFF's most extensively studied role is as part of an endogenous "anti-opioid" system that counterbalances opioid receptor signaling. The hypothesis, first advanced in the early 1990s, holds that chronic opioid exposure upregulates NPFF signaling as a homeostatic response, and that this upregulation contributes to the development of analgesic tolerance and physical dependence (Rothman, Synapse, 1992).
Supporting evidence from the rodent literature includes:
- •Withdrawal potentiation. In naloxone-precipitated morphine withdrawal models, exogenous NPFF significantly worsened withdrawal symptom severity, while the NPFF receptor antagonist dansyl-PQRamide attenuated the same syndrome (PubMed 10573293).
- •Receptor-selective reversal of tolerance. AC-263093, a small-molecule NPFFR2-selective agonist (without NPFFR1 activity), was shown to attenuate established morphine tolerance (PubMed 25459291).
- •Broad-spectrum NPFF receptor antagonism. RF9, a systemically active NPFF receptor antagonist, dose-dependently blocked the long-lasting hyperalgesia produced by acute fentanyl or chronic morphine administration, potentiated opioids' early analgesic effects, prevented the development of morphine tolerance, and reduced naltrexone-precipitated withdrawal severity — while, notably, potentiating morphine-induced conditioned place preference without producing reward on its own (PubMed 21718302).
- •Chronic mu-receptor downregulation. Sustained intracerebroventricular NPFF infusion has been shown to downregulate mu-opioid binding sites in rat brain, offering a receptor-level mechanism for tolerance (Rothman et al., Peptides, 1993).
Bifunctional opioid/NPFF ligands
Because pure NPFF receptor antagonism could theoretically be paired with opioid agonism to get analgesia without the downstream tolerance liability, a growing line of medicinal chemistry research has focused on dual-acting or "bifunctional" compounds that combine an opioid receptor agonist pharmacophore with an NPFF receptor antagonist or modulator pharmacophore in a single molecule:
- •BN-9, a bifunctional opioid/NPFF receptor agonist, produced potent spinal antinociception in mice without development of tolerance or opioid-induced hyperalgesia across repeated dosing (PubMed 32416184).
- •EN-9, a kappa-opioid/NPFF receptor bifunctional agonist, showed reduced tolerance after repeated dosing compared to morphine, though it retained cross-tolerance to morphine; blocking the NPFF receptor component reintroduced tolerance development, directly implicating NPFF receptor engagement as protective (PubMed 36410163).
- •More recent small-molecule dual opioid–NPFF ligands (2025) have demonstrated analgesia with reduced tolerance liabilities in preclinical models, an active area of ongoing structure-activity-relationship work (PMC12251305).
Taken together, this body of work positions the NPFF system as one of the more promising non-opioid-receptor targets for reducing the tolerance and dependence burden of opioid analgesics — a topic of considerable interest given the ongoing opioid crisis.
Cardiovascular and Renal Regulation
Beyond pain and opioid pharmacology, NPFF and its receptors are expressed in brain regions and peripheral tissues involved in blood pressure control. Centrally, NPFF acts within the brainstem and the hypothalamic paraventricular nucleus (PVN), where it produces distinct effects on magnocellular neurons (which govern neurohypophyseal hormone secretion) versus parvocellular neurons (which govern sympathetic outflow) (PMC11675822).
More recently, NPFF and both of its receptors have been identified in renal proximal tubules in mouse and human kidney tissue, where NPFF decreases forskolin-stimulated cAMP production in a concentration- and time-dependent manner — evidence of a local, autocrine NPFF signaling loop with a direct role in blood pressure regulation independent of central mechanisms (Renal autocrine NPFF signaling regulates blood pressure, Scientific Reports, 2024; PubMed 38965251). Altered NPFF and vasopressin system activity has also been reported in postmortem comparisons of normotensive versus hypertensive human brainstem tissue (Vasopressin and NPFF systems in hypertensive human brainstem).
Other Physiological Roles Under Study
- •Thermoregulation. Central NPFF administration influences core body temperature in rodent models, consistent with its dense expression in hypothalamic thermoregulatory circuits.
- •Feeding behavior and energy balance. NPFF has documented effects on food intake in rodent studies, and — since it shares its precursor gene with NPAF — is grouped with other RFamide peptides implicated in energy homeostasis alongside QRFP/26RFa and PrRP.
- •Neuroendocrine and reproductive crosstalk. Because NPFFR1 also responds to RFRP-1 and RFRP-3 (GnIH), the NPFF receptor system intersects with the reproductive-axis signaling more classically associated with kisspeptin and GnIH biology. Researchers studying the reproductive RFamide axis often reference NPFFR1 cross-reactivity when interpreting RFRP-3 pharmacology.
- •Monoamine system interaction. NPFF has been reported to modulate serotonergic and noradrenergic signaling, part of the broader mechanistic picture behind its anxiolytic- and stress-related research findings.
- •Immunity and nerve injury. Preclinical work has implicated the NPFF/NPAF gene products in immune modulation and peripheral nerve injury responses, though this remains an earlier-stage area of study relative to the opioid-interaction literature.
NPFF in the Research Toolkit: Agonists, Antagonists, and Selectivity
Because NPFFR1 and NPFFR2 can have opposing functional outputs, receptor selectivity is a central design consideration for any compound used in NPFF-pathway research:
| Compound class | Target | Reported research effect |
|---|---|---|
| NPFF (native peptide) | NPFFR1 + NPFFR2 (non-selective) | Anti-opioid effects; potentiates withdrawal and hyperalgesia |
| RF9 | NPFFR1 + NPFFR2 antagonist | Blocks opioid-induced hyperalgesia; prevents morphine tolerance |
| AC-263093 | NPFFR2-selective agonist | Attenuates established morphine tolerance |
| dansyl-PQRamide | Non-selective NPFF receptor antagonist | Attenuates naloxone-precipitated withdrawal |
| BN-9 / EN-9 | Bifunctional opioid agonist + NPFF receptor modulator | Antinociception with reduced tolerance liability |
The 2025 cryo-EM structures of NPFFR1 and NPFFR2 are expected to accelerate development of genuinely receptor-selective tool compounds, since prior structure-activity work was largely limited to functional assays rather than direct structural guidance (PubMed 40839429).
How NPFF Compares to Other RFamide Peptides
NPFF is one of several RFamide-family peptides under active study, each with a distinct receptor and physiological emphasis:
- •Kisspeptin — GPR54/KISS1R; primary driver of GnRH pulsatility and reproductive neuroendocrinology. See the site's Kisspeptin-10 research profile.
- •QRFP/26RFa — GPR103; orexigenic, tied to energy balance, bone metabolism, and adrenal cortex function. See the 26RFa/QRFP profile.
- •PrRP — GPR10; anorexigenic, stress and HPA-axis regulator. See the PrRP profile.
- •NPFF — NPFFR1/NPFFR2; anti-opioid modulation, pain, blood pressure, thermoregulation (this article).
Researchers comparing across this family should note that NPFFR1 cross-reacts with RFRP-1/RFRP-3 (the GnIH peptides), making receptor-selectivity controls especially important when interpreting NPFF-pathway data alongside reproductive-axis RFamide research.
Research Handling Considerations
NPFF is supplied by research chemical vendors in lyophilized powder form for in vitro and in vivo laboratory use. As with any research peptide:
- •Confirm third-party purity and identity documentation (HPLC/MS) before use — see the site's Research Grade vs. Pharmaceutical Grade Peptides guide for a breakdown of what to look for in a certificate of analysis.
- •Use the Peptide Reconstitution & Dosage Calculator to work out solvent volumes and stock concentrations for bench protocols — see the accompanying calculator guide for step-by-step instructions.
- •Store lyophilized peptide at -20°C and reconstituted stock per standard cold-chain practice for short RFamide octapeptides; avoid repeated freeze-thaw cycles.
NPFF is not intended for human administration. All applications described in this article originate from published in vitro and animal-model research and are provided strictly as a literature summary for laboratory researchers.
Frequently Asked Questions
Is neuropeptide FF the same as neuropeptide Y?
No. Despite the similar naming convention, NPFF and NPY are structurally and functionally distinct peptides with different receptor systems. NPY (see the site's Neuropeptide Y profile) signals through Y-receptors and is primarily studied for appetite and cardiovascular regulation; NPFF signals through NPFFR1/NPFFR2 and is primarily studied for its anti-opioid and pain-modulatory effects.
What does "anti-opioid" mean in the NPFF literature?
It refers to NPFF's reported ability to counteract or blunt opioid receptor-mediated analgesia over time, contributing to tolerance, and to potentiate opioid withdrawal symptoms — the opposite functional direction from an opioid agonist, even though NPFF does not itself bind opioid receptors directly.
Are NPFFR1 and NPFFR2 the same receptor?
No. They are separate GPCRs (68% sequence similarity) with distinct ligand preferences and, in several pain models, opposing functional roles — NPFFR1 as largely pro-nociceptive/anti-opioid, NPFFR2 as largely antinociceptive/opioid-potentiating.
Is NPFF FDA-approved?
No. NPFF has no FDA-approved indication and is not marketed as a drug or supplement. It is used exclusively in laboratory research settings.
References
1. Yang HY, et al. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc Natl Acad Sci USA. 1985.
2. Role of neuropeptide FF in central cardiovascular and neuroendocrine regulation. PMC3566396
3. Structural insights into the selective recognition of RF-amide peptides by neuropeptide FF receptor 2. PMC12069643
4. Structural basis of peptide recognition and modulation for neuropeptide FF receptors. Cell Reports, 2025. PubMed 40839429
5. Molecular recognition at the opioid-modulating neuropeptide FF receptor 1. Protein & Cell. PMC13107563
6. Modulation of naloxone-precipitated morphine withdrawal syndromes in rats by neuropeptide FF analogs. PubMed 10573293
7. Reversal of morphine tolerance by a compound with NPFF receptor subtype-selective actions. PubMed 25459291
8. Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments. PubMed 21718302
9. Spinal administration of BN-9 produced potent antinociception without tolerance and opioid-induced hyperalgesia. PubMed 32416184
10. Analgesic tolerance and cross-tolerance to EN-9 and mu-opioid receptor ligands. PubMed 36410163
11. Dual Opioid–Neuropeptide FF Small Molecule Ligands Demonstrate Analgesia with Reduced Tolerance Liabilities. PMC12251305
12. Renal autocrine neuropeptide FF (NPFF) signaling regulates blood pressure. Scientific Reports, 2024. PubMed 38965251
13. An Overview on Renal and Central Regulation of Blood Pressure by Neuropeptide FF and Its Receptors. PMC11675822
14. Vasopressin (VP) and neuropeptide FF (NPFF) systems in the normal and hypertensive human brainstem. Wiley
This article is for research and educational purposes only. It does not constitute medical advice and NPFF is not approved for human use.